MedPath

Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)

Phase 3
Active, not recruiting
Conditions
Biliary Atresia
Interventions
Drug: Placebo
Registration Number
NCT04336722
Lead Sponsor
Albireo, an Ipsen Company
Brief Summary

Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in children with biliary atresia who have undergone a Kasai hepatoportoenterostomy.

Detailed Description

Up to 70 sites will be initiated for this study in North America, Europe, Middle East, and Asia Pacific.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
254
Inclusion Criteria
  • A male or female patient with a clinical diagnosis of BA
  • Age at Kasai HPE ≤90 days
  • Eligible to start study treatment within 3 weeks post-Kasai HPE

Key

Exclusion Criteria
  • Patients with intractable ascites
  • Ileal resection surgery
  • ALT ≥10× upper limit of normal (ULN) at screening
  • Patients reliant only on total parenteral nutrition, or not able to take study medication orally, at randomization
  • Acute ascending cholangitis (patients may be randomized after resolution of acute ascending cholangitis)
  • Choledochal cystic disease
  • INR >1.6 (the patient may be treated with Vitamin K intravenously; sample may be redrawn and if INR is ≤1.6 at resampling the patient may be randomized)
  • Any other conditions or abnormalities, including congenital abnormalities, major cardiac surgery, hepatic, biliary, or GI disease which, in the opinion of the Investigator or Medical Monitor, may compromise the safety of the patient, the integrity of study results, or patient compliance with study requirements
  • Weight <3.5kg at randomization

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Odevixibat (A4250)OdevixibatCapsules for oral administration once daily for 104 weeks.
PlaceboPlaceboCapsules for oral administration (to match active) once daily for 104 weeks.
Primary Outcome Measures
NameTimeMethod
Time from randomization to first occurrence of liver transplant, or deathFrom baseline to Week 104
Secondary Outcome Measures
NameTimeMethod
Time to onset of any sentinel eventsFrom baseline to Week 104

Time to onset of any sentinel events

Serum bile acid levelsFrom baseline to Weeks 13, 26, 52 and 104

Serum bile acid level after 13, 26, 52, and 104 weeks of study treatment

Time to pediatric end-stage liver disease (PELD) score >15From baseline to Week 104

Time to pediatric end-stage liver disease (PELD) score \>15

Percentage of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)From baseline to Week 104

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Percentage of participants with clinically significant changes in Physical ExaminationFrom baseline to Week 104

Percentage of participants with clinically significant changes in physical examination findings will be reported. The clinical significance will be graded by the investigator.

Percentage of participants with clinically significant changes in Laboratory Parameters (blood chemistry, hematology and coagulation)From baseline to Week 104

Percentage of participants with clinically significant change in laboratory parameters (blood chemistry, hematology and coagulation) will be reported. The clinical significance will be decided by the investigator.

Percentage of participants with clinically significant changes in Abdominal Ultrasound findingsFrom baseline to Week 26 and Week 104

Percentage of participants with clinically significant change in Abdominal Ultrasound findings will be reported. The clinical significance will be decided by the investigator.

Proportion of patients with liver transplantFrom baseline to Week 104

Proportion of patients who are alive and have not undergone a liver transplant

Total bilirubin levelsFrom baseline to Weeks 13, 26, 52 and 104

Total bilirubin level after 13, 26, 52, and 104 weeks of study treatment

Trial Locations

Locations (66)

Children's Healthcare of Atlanta - Emory University School of Medicine

🇺🇸

Atlanta, Georgia, United States

Johns Hopkins Children's Center

🇺🇸

Baltimore, Maryland, United States

Seattle Children's Hospital

🇺🇸

Seattle, Washington, United States

UZ Gent

🇧🇪

Gent, Belgium

UCSF Benioff Children's Hospital San Francisco

🇺🇸

San Francisco, California, United States

Indiana University school of Medicine

🇺🇸

Indianapolis, Indiana, United States

Cincinnati Children's Hospital

🇺🇸

Cincinnati, Ohio, United States

University of Utah

🇺🇸

Salt Lake City, Utah, United States

The Hospital for Sick Children

🇨🇦

Toronto, Canada

Meyer Children´s University Hospital

🇮🇹

Florence, Italy

Bicêtre Hospital

🇫🇷

Le Kremlin-Bicêtre, France

Schneider Children´s Medical Center of Israel

🇮🇱

Petah tikva, Israel

The Children's Hospital at Montefiore

🇺🇸

Bronx, New York, United States

Children's Mercy Hospital

🇺🇸

Kansas City, Missouri, United States

Hôpital Femme Mère Enfant

🇫🇷

Bron, France

Cleveland Clinic

🇺🇸

Cleveland, Ohio, United States

University of Michigan Children's Hospital

🇺🇸

Ann Arbor, Michigan, United States

CHU Sainte-Justine

🇨🇦

Montréal, Canada

University Hospital of Padova

🇮🇹

Padova, Italy

NYU Grossman school of Medicine

🇺🇸

New York, New York, United States

Nemours/Alfred I. duPont Hospital for Children

🇺🇸

Wilmington, Delaware, United States

Guangzhou Women and Children's Medical Center

🇨🇳

Guangzhou, Guangdong, China

Ospedale Pediatrico Bambino Gesù

🇮🇹

Roma, Italy

UT Southwestern Medical Center

🇺🇸

Dallas, Texas, United States

University of Malaya Medical Centre

🇲🇾

Kuala Lumpur, Malaysia

University Medical Center Groningen

🇳🇱

Groningen, Netherlands

Akdeniz University Medical Faculty

🇹🇷

Antalya, Turkey

Hannover Medical School

🇩🇪

Hanover, Germany

Charité - Universitätsmedizin Berlin

🇩🇪

Berlin, Germany

University Children´s Hospital Tuebingen

🇩🇪

Tuebingen, Germany

Hospital Universitari Vall d'Hebron

🇪🇸

Barcelona, Spain

Rady Children's Hospital

🇺🇸

San Diego, California, United States

Children's National Medical Center

🇺🇸

Washington, District of Columbia, United States

Ann & Robert H. Lurie Children's Hospital

🇺🇸

Chicago, Illinois, United States

Boston Children's Hospital

🇺🇸

Boston, Massachusetts, United States

NewYork-Presbyterian Morgan Stanley Children's Hospital

🇺🇸

New York, New York, United States

UPMC Children's Hospital of Pittsburgh

🇺🇸

Pittsburgh, Pennsylvania, United States

The Children´s Hospital of Philadelphia

🇺🇸

Philadelphia, Pennsylvania, United States

Oregon Health & Science University

🇺🇸

Portland, Oregon, United States

The Children´s Hospital at Westmead

🇦🇺

Sydney, Australia

Royal Children's Hospital

🇦🇺

Parkville, Australia

Children's Hospital of Fudan University

🇨🇳

Shanghai, China

Jeanne de Flandre Hospital

🇫🇷

Lille, France

Necker University Hospital - Enfants malades

🇫🇷

Paris, France

University Medical Center Hamburg-Eppendorf UKE

🇩🇪

Hamburg, Germany

Leeds General Infirmary

🇬🇧

Leeds, United Kingdom

Semmelweis Egyetem I.sz Gyermekgyógyászati Klinika

🇭🇺

Budapest, Hungary

ASST Papa Giovanni XXIII

🇮🇹

Bergamo, Italy

ISMETT - Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione

🇮🇹

Palermo, Italy

Regina Margherita Children´s Hospital

🇮🇹

Turin, Italy

Samsung Medical Center

🇰🇷

Seoul, Korea, Republic of

Hospital Raja Perempuan Zainab II

🇲🇾

Kota Bharu, Malaysia

Seoul National University Children's Hospital

🇰🇷

Seoul, Korea, Republic of

National Taiwan University Hospital

🇨🇳

Taipei, Taiwan

Instytut Pomnik-Centrum Zdrowia Dziecka

🇵🇱

Warsaw, Poland

Birmingham Women´s and Children´s Hospital

🇬🇧

Birmingham, United Kingdom

Istanbul University, Istanbul Medical Faculty

🇹🇷

Istanbul, Turkey

Hacettepe University Ihsan Dogramaci Childrens Hospital

🇹🇷

Ankara, Turkey

Children's Hospital Colorado

🇺🇸

Aurora, Colorado, United States

Washington University in St. Louis

🇺🇸

Saint Louis, Missouri, United States

Starship Child Health

🇳🇿

Auckland, New Zealand

Medical College of Wisconsin

🇺🇸

Milwaukee, Wisconsin, United States

Stanford Children's Health

🇺🇸

Palo Alto, California, United States

Children's Hospital Los Angeles

🇺🇸

Los Angeles, California, United States

University of Miami

🇺🇸

Miami, Florida, United States

Icahn School of Medicine at Mount Sinai

🇺🇸

New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath